



FORM PTO-1390 (REV. 1-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER H8610/259296
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/856938
INTERNATIONAL APPLICATION NO. PCT/GB99/03997	INTERNATIONAL FILING DATE 30 November 1999	PRIORITY DATE CLAIMED 30 November 1998	
TITLE OF INVENTION WOOD PRESERVATIVE FORMULATIONS			
APPLICANT(S) FOR DO/EO/US WILLIAMS, Gareth; BACON, Michael			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 37 (b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unexecuted) <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.197 and 1.98 <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: <p>I hereby certify that this Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. 371, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the 30th day of May 2001 in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Mailing Label Number EL670008705US addressed to the Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.</p> <p style="text-align: right;"><i>Odessa Roberts</i></p>			

U.S. APPLICATION NO. (Information, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
09/856938		PCT/GB99/03997		H8610/259296	
17. <input checked="" type="checkbox"/> The following fees are submitted BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	13 - 20 =	0	X \$18.00	\$ 0.00	
Independent claims	3 - 3 =	0	X \$80.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 270.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 1260.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) --				\$ 0.00	
SUBTOTAL =				\$ 1260.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1260.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 1260.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1260.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. 11-0855 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-0855. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.					
CORRESPONDENCE ADDRESS:		CUSTOMER NUMBER BAR CODE LABEL:		SIGNATURE	
John S. Pratt, Esq.					
KILPATRICK STOCKTON LLP		23370		Name: Bruce D. Gray	
1100 Peachtree Street, Suite 2800		PATENT TRADEMARK OFFICE		Registration No. 35,799	
Atlanta, Georgia 30309-4530					

Wood Preservative Formulations

5 This invention relates to preservatives for wood and other materials, in particular to preservative formulations which contain an oxathiazine.

The use of oxathiazines in wood preservation is known (WO 95/06043 of Uniroyal Chemical Company, Inc.).
10 These oxathiazines are most active against the soft rot fungi *Ascomycotina* and *Deuteromycotina*. These organisms are often responsible for significant degradation of wood in practice (Eaton and Hale (1993)).

As with most individual active ingredients,
15 oxathiazines by themselves do not provide protection against all fungi, bacteria, and other microorganisms which it is desirable to protect wood or other materials against. Therefore, WO 95/06043 discusses the possibility of enhancing the spectrum of activity by
20 addition of other active ingredients, binding agents, co-solvents etc.

Organic wood preservative formulations such as, those containing oxathiazines are expensive to formulate and manufacture and improvements in their performance
25 against fungi, particularly *Ascomycotina* and *Deuteromycotina*, would therefore be of benefit to the wood preservative industry.

Surprisingly, it has been found that by addition of certain other organic biocides, the efficacy of the
30 oxathiazine-based formulations is significantly increased. In the case of some oxathiazines which have on their own poor efficacy, the addition of other organic biocides results in formulations having excellent efficacy, particularly against *Ascomycotina* and *Deuteromycotina*.
35

We have found that for an increase in activity of oxathiazine containing formulations against *Ascomycotina*

and *Deuteromycotina*, it is not a requirement that the additional organic biocides themselves have good activity against these fungi. A synergistic relationship has been observed, whereby oxathiazines and other organic biocides having individually moderate or poor efficacy against *Ascomycotina* and *Deuteromycotina*, when present together in a formulation provide a highly effective wood preservative agent.

The additional organic biocide is a quaternary ammonium compound or a triazole compound.

According to one aspect therefore, the present invention provides a preservative composition comprising, in synergistic proportions, an oxathiazine compound plus one or more of a quaternary ammonium compound and a triazole compound.

Particularly preferred compositions according to the invention comprise, in synergistic proportions, an oxathiazine compound, a quaternary ammonium compound and a triazole compound.

In a further aspect, the invention provides a method of preserving wood or other material which comprises applying to the wood or other material a composition comprising an oxathiazine compound plus one or more of a quaternary ammonium compound and a triazole compound in synergistic proportions.

The other materials besides wood which can benefit from treatment with the formulations of the invention include cellulosic material such as cotton. Also, leather, textile materials and even synthetic fibres, hessian, rope and cordage as well as composite wood materials. For convenience, the invention will be described with reference to the treatment of wood but it will be appreciated that other materials may be treated analogously.

The application of these compositions may be by dipping, spraying, brushing or other surface coating means or by high pressure or double vacuum impregnation

- 3 -

into the body of the wood or other material, all being techniques well known to the man skilled in the art. Impregnation under pressure is particularly advantageous when the substrate is wood or a wood composite material which is made to become wet during its life, for example, wood for window frames, timber used above ground in exposed environments such as decking and timber used in ground contact or fresh water or salt water environments.

According to a further aspect of the invention there is provided the use of a quaternary ammonium compound or a triazole to enhance the activity of an oxathiazine against *Ascomycotina* and *Deuteromycotina*.

Substrates made of wood or other material which have been treated with a composition or by a method according to the invention as described herein, comprise further aspects of the present invention.

Certain compositions according to the invention are particularly advantageous from an environmental point of view, as they provide excellent heavy metal free compositions for protecting wood when it is in contact with soil, as the oxathiazine additionally protects the wood against soil bacteria such as *Alcaligenes*, *Bacillus*, *Clostridium*, *Pseudomonas*, etc.

Preferably, the compositions are applied to timber components before they are used in construction but they can also be used remedially as a curative action in preventing continued wood degradation or defacement.

- 4 -

Oxathiazine compounds for use in the present invention include, for example, oxathiazine compounds of formula (I)



10 wherein n is 0, 1 or 2; R¹ is hydrogen, C₁-C₄ linear or branched alkyl, or benzyl; and

R is:

(a) phenyl; naphthyl; phenyl substituted with 1 to 3 of the following substituents:


15 hydroxyl, halo, C₁-C₁₂ alkyl, C₅-C₆ cycloalkyl, trihalomethyl, phenyl, C₁-C₅ alkoxy, C₁-C₅ alkylthio, tetrahydropyranyloxy, phenoxy, (C₁-C₄ alkyl)carbonyl, phenylcarbonyl, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, carboxy or its alkali metal
20 salt, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄ alkyl)aminocarbonyl, phenylaminocarbonyl, tolylaminocarbonyl, morpholinocarbonyl, amino, nitro, cyano, dioxolanyl, or (C₁-C₄ alkoxy)iminomethyl;

25 pyridinyl; thienyl, preferably when n is not 2; furanyl; or thienyl or furanyl substituted with 1 to 3 of the following groups:

alkyl, alkoxy, alkylthio, alkoxycarbonyl, halogen, trihalomethyl, cyano, acetyl, benzoyl, nitro, formyl, alkoxyaminomethyl, phenyl, or phenylaminocarbonyl, wherein the alkyl or alkoxy moiety is C₁-C₄, linear or branched;


or

(b)



wherein X is oxygen or sulfur; Y is nitrogen, -CH-, or -C(C₁-C₄ alkoxy)-; and R" is hydrogen or C₁-C₄ alkyl.

Preferably the oxathiazine compound has the formula (II)



(II)

wherein n is 0, 1 or 2, R¹ is hydrogen, C₁-C₄ linear or branched alkyl, or benzyl; and

Q is:

(a)



wherein R², R³ and R⁴ are, individually, hydrogen, alkyl, alkoxy, alkylthio, alkoxycarbonyl, halogen, trihalomethyl, cyano, acetyl, formyl, benzoyl, nitro, alkoxyaminomethyl, phenyl, or phenylaminocarbonyl, wherein the alkyl or alkoxy moieties are all C₁-C₄, linear or branched, with the proviso that at least one of R², R³ or R⁴ must be other than hydrogen;


(b)



wherein R⁵, R⁶ and R⁷ are, individually, hydrogen, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halogen, trihalomethyl, cyano, acetyl, formyl, benzoyl, nitro, phenyl, or


phenylaminocarbonyl, with the proviso that at least one of R^5 , R^6 or R^7 must be other than hydrogen;

(c)



wherein R^8 , R^9 and R^{10} are, individually, hydroxyl, halo, C_1 - C_{12} alkyl, C_5 - C_6 cycloalkyl, trihalomethyl, phenyl, C_1 - C_5 alkoxy, C_1 - C_5 alkylthio, tetrahydropyranyloxy, phenoxy, (C_1 - C_4 alkyl)carbonyl, phenylcarbonyl, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, carboxy or its alkali metal salt, (C_1 - C_4 alkoxy)carbonyl, (C_1 - C_4 alkyl)aminocarbonyl, phenylaminocarbonyl, tolylaminocarbonyl, morpholinocarbonyl, amino, nitro, cyano, dioxolanyl, or (C_1 - C_4 alkoxy)iminomethyl; or

(d)



wherein X is oxygen or sulfur; Y is nitrogen, -CH-, or -C(C_1 - C_4 alkoxy)-; and R^n is hydrogen or C_1 - C_4 alkyl.

More preferably, the oxathiazine is a compound of formula II wherein

R^1 is hydrogen or C_1 - C_4 alkyl; n is 1 or 2;

R^2 , R^3 and R^4 are, individually, hydrogen, C_1 - C_4 alkyl, halo, (C_1 - C_4 alkoxy)-carbonyl, or cyano, with the proviso that at least one of R^2 , R^3 and R^4 must be other than hydrogen;

R^5 , R^6 and R^7 are, individually, hydrogen, halo or cyano, with the proviso that at least one of R^5 , R^6 and R^7 must be other than hydrogen;

R^8 , R^9 and R^{10} are C_1 - C_4 alkyl, C_1 - C_4 alkoxy, nitro, halo, trihalomethyl, or (C_1 - C_4 alkoxy)-carbonyl; X is

sulfur; and R" is hydrogen.


More preferred are those compounds of formula (II) wherein R¹ is hydrogen; n is 1 or 2;

R², R³ and R⁴ are, individually, hydrogen, methyl, ethyl, bromo, chloro, ethyl carboxylate, or cyano, with the proviso that at least one of R², R³ and R⁴ must be other than hydrogen;


R⁵, R⁶ and R⁷ are, individually, hydrogen, bromo, chloro, or cyano, with the proviso that at least one of R⁵, R⁶ and R⁷ must be other than hydrogen;

R⁸, R⁹ and R¹⁰ are methyl, ethyl, nitro, fluoro, chloro, or trifluoromethyl.


The most preferred oxathiazine compounds for use in the compositions and methods of the present invention are 3-(benzo[b]thien-2-yl)-5,6-dihydro-1,4,2-oxathiazine 4-oxide, hereinafter referred to as bethoxazin and 5,6-dihydro-3-(2-thienyl)-1,4,2-oxathiazine, 4-oxide,



Preferably the triazole compound contains the triazole group



Advantageously, the triazole compound is selected from compounds of formula (A):




wherein R₁ represents a branched or straight chain

C₁₋₅ alkyl group (e.g. t-butyl) and R₂ represents a phenyl group optionally substituted by one or more substituents selected from halogen (e.g. chlorine, fluorine or bromine) atoms or C₁₋₃ alkyl (e.g. methyl), C₁₋₃ alkoxy (e.g. methoxy), phenyl or nitro groups.

A particularly preferred compound of formula (A) is tebuconazole:

alpha-[2-(4-chlorophenyl)ethyl]-alpha(1,1-dimethylethyl)-1H-1,2,4-triazole-1-ethanol.

Alternatively, the triazole compound is advantageously selected from compounds of formula (B):



(B)

wherein R₃ is as defined for R₂ above and R₄ represents a hydrogen atom or a branched or straight chain C₁₋₅ alkyl group (e.g. n-propyl).


Particularly preferred triazole compounds of this type are: propiconazole (1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole) and azaconazole (1-[[2,4-dichlorophenyl)-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole. Other triazoles which could be used include hexaconazole ((RS)-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol), difenaconazole, cyproconazole ((2RS,3RS; 2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol), bromuconazole (1-[4-bromo-2-(2,4-dichlorophenyl)tetrahydrofurfuryl]-1H-1,2,4-triazole), epoxiconazole (1-[3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-ylmethyl]-1H-1,2,4-triazole), metconazole (5-[(4-chlorophenyl)-methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol), and triticonazole ((E)-5-(4-chlorophenyl)methylene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)-cyclopentanol),

fenbuconazole, flusilazole, tetraconazole and penconazole.

Compositions according to the invention may contain more than one triazole compound, for example, they may contain two or more triazoles selected from tebuconazole, propiconazole, azaconazole and cyproconazole, such as tebuconazole and propiconazole, tebuconazole and cyproconazole or a mixture of tebuconazole, propiconazole and azaconazole.

Of the quaternary ammonium compounds which may be used in the compositions and methods of the present invention, suitable compounds include:

1. Monoalkyltrimethyl ammonium salts of formula (III):




(III)

wherein R is an alkyl group having between 6 and 18 carbon atoms, preferably between 12 and 14 carbon atoms and X⁻ is an anion chosen to allow ready water solubility of the quaternary ammonium salt. Examples being : chloride, bromide, sulphate, acetate, propionate, lactate, citrate, methosulphate and carbonate.

Preferred examples include Cocotrimethyl ammonium chloride in which the alkyl group R consists of a mixture of predominantly C₁₂ and C₁₄.

2. Dialkyl dimethyl ammonium salts of formula (IV):




(IV)


wherein R_1 and R_2 are alkyl groups which may be the same or different and which contain between 6 and 18 carbon atoms, preferably between 8 and 10 carbon atoms and X^- is an anion of the type previously described.

Preferred examples include Didecyl dimethyl ammonium chloride, dioctyl dimethyl ammonium chloride and octyl decyl dimethyl ammonium chloride either individually or as a mixture containing two or three of these.

3. Alkyl dimethyl benzyl ammonium salts and dialkyl methyl benzyl ammonium salts of formulae (V) or (VI).



(V)




(VI)


wherein R_1 and R_2 are alkyl groups which can be the same or different and which contain between 6 and 18 carbon atoms, preferably between 8 and 10 carbon atoms in a dialkyl compound and between 10 and 14 carbon atoms in a monoalkyl compound and X^- is an anion of the type previously described.

Preferred examples include Coco benzyl dimethyl ammonium chloride and dicoco benzyl methyl ammonium chloride in which the alkyl groups are predominantly C_{12} and C_{14} .

4. Alkyl and dialkyl oxyethylene methyl ammonium salts of formulai (VII) or (VIII):



(VII)



(VIII)

wherein R_1 and R_2 are alkyl groups which may be the same

or different and which contain between 6 and 18 carbon atoms, preferably between 8 and 10 carbon atoms in a dialkyl compound and between 10 and 14 carbon atoms in a monoalkyl compound, most preferably 10 carbon atoms. m is a number between 1 and 20 typically between 1 and 8, preferably between 3 and 5. X⁻ is an anion of the type previously described, preferably propionate or lactate.

Preferred examples include N,N-didecyl-N-methyl-poly(oxyethyl) ammonium propionate (Bardap 26) or N,N-didecyl-N-methyl-poly(oxyethyl) ammonium lactate.

5. Polymeric quaternary ammonium compounds in which active quaternary ammonium compounds are chemically grafted to a polymer backbone.

Compositions containing quaternary ammonium compounds can form micro-emulsions which are particularly useful in the treatment of timber. In addition, the presence of these compounds means that additional organic solvents may not be necessary to solubilise the triazole compound if such a compound is also present in the formulation. The inclusion of quaternary ammonium compounds may also improve penetration of the triazole compound into the timber.

The optimum weight ratio of the oxathiazine compound to the other organic biocide varies depending on the particular material to which the composition is applied, the type of organism against which protection is required and the precise conditions to which the treated material will be exposed. However, preferably, the weight ratio of oxathiazine compound to triazole and/or quaternary ammonium compound should be between 100:1 and 1:100 or 50:1 and 1:50, more preferably between 20:1 and 1:20 or 5:1 and 1:10, typically between 2:1 and 1:5. In certain preferred formulations according to the invention, the quaternary ammonium compounds will be present in excess of the oxathiazine

or triazole compound. The triazole and oxathiazine compound may be present in about equal amounts (e.g. 2:1 to 1:2 on a weight basis) and at least as much quarternary ammonium compound may be present, either as much as one of the other ingredients or as much as both of them together. For example, the ratio of quaternary ammonium compound to oxathiazine may advantageously be 1:1 to 8:1 preferably 2:1 to 5:1 on a w/w basis.

The concentration of the formulation required for preservative treatment depends on the ratio of oxathiazine to triazole or quaternary ammonium compound selected, the method of treatment employed, the timber species, the level of protection required and the nature and quantity of any other biocides present. The amounts necessary can be determined readily by one skilled in the art. In general, the amount of oxathiazine will be in the range 0.01-1.0 kgm⁻³, the amount of triazole in the range 0.1-10.0 kgm⁻³ and the amount of quaternary ammonium compound will be in the range 0.1-10.0 kgm⁻³; all values are expressed as the weight per unit volume of wood treated.

Conveniently, the compositions of the present invention are applied as a liquid composition, preferably by high pressure impregnation. They may also be applied as a solid implant or paste. Preferably, when applied in liquid form, this is in an aqueous solution, but one or more organic solvents or a mixture of water and an organic solvent could also be used. Suitable organic solvents include both aromatic and aliphatic hydrocarbon solvents such as white spirit, petroleum distillate, kerosene, diesel oils and naphthas. Also, benzyl alcohol, 2-phenoxy ethanol, methyl carbitol, propylene carbonate, benzyl benzoate, ethyl lactate and 2-ethyl hexyl lactate. Formulations can be prepared as concentrates intended to be diluted at the treatment facility, or the formulations can be prepared in the form of dilute treatment solutions.

The compositions according to the invention may additionally, comprise other active ingredients such as termiticides, insecticides, bacteriocides and other fungicides. Suitable additional fungicides would be apparent to one skilled in the art and will vary according to the application. In particular, additional fungicides which extend the spectrum of activity of the formulation may be chosen, such as fungicides active against bluestain fungi, white rots, brown rots, dry rots and moulds. Suitable additional fungicides include for example, dichlofluanid, acypetacs, imazalil, IPBC, isothiazolones, tolylfluanid, chlorothalonil, benzimidazoles, as well as metal compounds such as copper, Cu-oxide and Cu-HDO, also iron and zinc and salts, compounds and soaps thereof. Suitable insecticides would also be apparent to the skilled man depending upon the intended application, and include, for example, chlorpyrifos, cypermethrin, fenvalerate, fipronil, farox, teramethrin, isofenphos, permethrin, silafluofen, deltamethrin, bifenthrin, cyfluthrin and imidacloprid, and benzoyleureas such as lufenuron, hexaflumuron and flufenoxuron and in particular, flurox.

The compositions according to the invention may additionally comprise other components which may act to improve the characteristics of the wood treated with these biocides. Such compounds could include water repellents based on waxes, silicones and polysiloxanes, latex, fluorocarbon, organic carboxylate/metals, paper sizing agents or amine oxides, or combinations thereof; crosslinking agents based on alkyds, acrylics, polyurethanes, formaldehydes, dimethylol, and epichlorohydrin or combinations thereof. Oils may also be used as may UV absorbers, corrosion inhibitors and defoamers.

The following non-limiting Examples further illustrate the invention.

A: Examples of formulations according to the invention for use in the preservation of wood and other materials

Those formulations which do not contain water are preferably made by weighing together all the components and blending to produce clear homogenous systems. Heating to not above 50°C may be necessary to ensure rapid dissolution of the solid active components in the solvents. Alternative methods of manufacture are possible such as solubilising the active components in water with surfactants.

Oil in water emulsions or micro-emulsions of these formulations can be prepared by adding the concentrates prepared as above to water at room temperature with good agitation to ensure proper dispersion. Emulsions containing any desired level of active component can be prepared in this way.

Those formulations containing water are formed into concentrated emulsions by taking firstly the non water containing components and blending them as for the anhydrous formulations. The required water is then added to the other components after the temperature has been allowed to return to ambient with efficient stirring to produce the concentrated emulsion. These emulsions can later be diluted to the required strength simply by adding to more water with mixing to produce diluted emulsions.

In the following Examples, Bardap 26 refers to N,N-didecyl-N-methyl-poly(oxyethyl) ammonium propionate. In all cases, the Bardap 26 preparation contains 70% of active ingredient.

Example 1

BARDAP 26/BETHOXAZIN/CYPROCONAZOLE 10:2:1

5		<u>% w/w</u>
	Bardap 26	14.29
	Bethoxazin	2.00
	Cyproconazole	1.00
	Methyl diethoxol	66.71
10	Nonylphenol 12EO	16.00

Example 2

BETHOXAZIN/CYPROCONAZOLE 2:1

15		<u>% w/w</u>
	Bethoxazin	1.334
	Cyproconazole	0.666
	Methyl diethoxol	18.000
	Dowanol PnB	10.000
20	Mineral oil	60.000
	Tridecanol 10EO	10.000

Example 325 BARDAP 26/BETHOXAZIN/TEBUCONAZOLE/PROPICONAZOLE
10:2:0.5:0.5

		<u>% w/w</u>
	Bardap 26	14.29
	Bethoxazin	2.00
30	Tebuconazole	0.72
	Propiconazole	0.72
	Butyl glycollate	15.35
	Diethyl phthalate	46.92
	Nonyl phenol 9EO	20.00

35

Example 4

BARDAP 26/BETHOXAZIN 10:2

		<u>% w/w</u>
5	Bardap 26	14.29
	Bethoxazin	2.00
	Dowanol DPM	21.79
	Aromatic solvent	44.42
	Castor oil 65EO	17.5

10

Example 5

BETHOXAZIN/TEBUCONAZOLE/PROPICONAZOLE 2:1:1

		<u>% w/w</u>
15	Bethoxazin	2.50
	Tebuconazole	1.25
	Propiconazole	1.25
	Benzyl alcohol	14.60
20	Methyl octoate	58.40
	Castor oil 40EO	22.00

Example 6

25 BETHOXAZIN/TEBUCANOZOLE 2:1

		<u>% w/w</u>
	Bethoxazin	3.33
	Tebuconazole	1.67
	Butyl glycollate	23.10
30	Diocetyl phthalate	53.90
	Nonylphenol 12EO	18.00

Example 7

35 BARDAP 26/BETHOXAZIN/IRON 10:2:1

		<u>% w/w</u>
	Bardap 26	14.29

- 17 -

	Bethoxazin	2.00
	Iron naphthenate*	10.00
	Oleyl alcohol 5EO	5.00
	Oleyl alcohol 10EO	7.50
5	Dowanol PnB	15.00
	Mineral oil	46.21

* Iron naphthenate in solvent containing 10.00% w/w iron metal

10

Example 8

BARDAP 26/BETHOXAZIN/IRON 10:2:1

Using complexed iron compound

15		<u>% w/w</u>
	Bardap 26	14.29
	Bethoxazin	2.00
	Iron EDTA*	11.11
	Butyl glycollate	23.36
20	Tridecanol 15EO	12.50
	Water	36.74

* Contains 9.0% w/w iron metal

25

Example 9

BARDAP 26/BETHOXAZIN/CYPROCONAZOLE/COPPER 10:2:1:1

		<u>% w/w</u>
30	Bardap 26	7.15
	Bethoxazin	1.00
	Cyproconazole	0.50
	Copper gluconate*	3.57
	Methyl diethoxol	14.50
35	Dowanol PnB	25.65
	Tridecanol 13EO	15.00
	Water	32.63

* Contains 14% copper metal

Example 10

5 BARDAP 26/BETHOXAZIN/Cyproconazole 10:2:1 plus Flurox

	<u>% w/w</u>
Bardap 26	14.28
Bethoxazin	2.00
10 Cyproconazole	1.00
Flurox	1.00
Methyl diethoxol	65.71
Nonyl phenol 12EO	16.00

15 Example 11

BARDAP 26/BETHOXAZIN + Farox 10:2 plus Farox

	<u>% w/w</u>
Bardap 26	14.28
20 Bethoxazin	2.00
Farox	1.50
Dowanol DPM	21.29
Aromatic solvent	43.42
Castor oil 65EO	17.51

25

Example 12

BETHOXAZIN/Tebuconazole 2:1 + Cypermethrin

	<u>% w/w</u>
30 Bethoxazin	3.33
Tebuconazole	1.67
Cypermethrin	2.00
Butyl glycolate	22.10
35 Dioctyl phthalate	52.90
Nonyl phenol 12EO	18.00

Example 13

Bardap 26/BETHOXAZIN/Iron 10:2:1 + Cyfluthrin

5		<u>% w/w</u>
	Bardap 26	14.29
	Bethoxazin	2.00
	Cyfluthrin	1.00
	Iron EDTA*	11.11
10	Butyl glycolate	22.86
	Tridecanol E015	12.00
	Water	36.74

* contains 9% w/w iron metal.

Example 14BARDAP 26/BETHOXAZIN/TEBUCONAZOLE/PROPICONAZOLE
10:2:0.5:0.5

20		<u>% w/w</u>
	Bardap 26	14.29
	Bethoxazin	2.00
	Tebuconazole	0.5
	Propiconazole	0.5
25	Butyl glycollate	15.79
	Diocetyl phthalate	46.92
	Nonyl phenol 9EO	20.00

30 Synergistic action of mixtures formulated according to the invention

The toxic limit value for a particular biocidal compound is the concentration of the compound which is required to prevent degradation (defined as >3% mass loss) of a substrate by a target organism. Toxic limits are normally expressed as two experimentally-determined

concentrations that span the pass/fail point of the test. The toxic index is the midpoint of these two values. Where a preservative composition contains two biocidal compounds at a particular ratio, the toxic index is the estimated minimum concentration of each biocide required for effective protection of the substrate from the target organism. In Figure 1 of the accompanying drawings, points A and B are the toxic index values for biocidal compounds Y and X respectively and the straight line between these two points illustrates the toxic index values which would be obtained if the biocidal effects of compounds X and Y are merely additive. If, for any particular ratio of X:Y, the toxic index value is found to be below the straight line (e.g. at point C), then compounds X and Y are synergistic at that particular ratio.

A convenient method of assessing the synergistic properties of a formulation is to use a 'synergistic index'. This may be defined as:

$$\text{Synergistic Index (SI)} = \frac{\text{Theoretical toxic index}}{\text{Actual toxic index}}$$

The theoretical toxic index may be calculated by interpolation to the theoretical line of action. A SI of 1 indicates no synergism. As the SI increases, so the degree of synergism also increases.

B: Wood Preservative Efficacy

Testing was carried out to determine the performance of active ingredients alone and in mixture using a soft rot soil burial method. The method used is similar to that described by the European pre-standard ENV-807 and challenges the treated wood in a wet soil environment to soft rot fungi belonging to the groups *Ascomycotina* and

Deuteromycotina.

Beech (*Fagus sylvatica*) blocks measuring 5 x 15 x 30 mm were prepared from local grown, seasoned, knot-free sapwood. After oven drying and weighing, the blocks were vacuum impregnated (in groups of 6 replicates) with retentions of the test preservatives which had been freshly prepared using deionised water as the diluent.

The following preservative combinations were tested:

Bethoxazin/Propiconazole (1:1)

Bethoxazin/Propiconazole/Tebuconazole (2:1:1)

Bethoxazin/Bardap 26 (1:5)

Bethoxazin/Bardap 26/Cyproconazole (2:10:1)

After treatment, the blocks were covered with polythene for a period of one week to reduce the drying rate and allow any fixation reactions to occur. They were then fully ventilated by standing on the laboratory bench for 2 weeks and allowed to dry.

Each series of blocks was then exposed in John Innes (No. 2) compost, previously wetted to 110% of water holding capacity using deionised water. The test systems were then incubated for 14 weeks at 28°C.

Following incubation, blocks were removed from the soil, gently rinsed in clean water and then oven dried and re-weighed.

Preservative retention and weight change data were calculated for each block and the results expressed as toxic limit values according to the criteria laid down in the test method EN113.

Results of Efficacy Testing

The results of the efficacy tests are given in the following table and expressed as toxic limit values in kgm^{-3} active ingredient retention.

Table 1

Results of Soil Testing with Organic Biocides	
Fungicide	Toxic Limit Value (kgm^{-3})
Tebuconazole	> 7.0
Propiconazole	> 7.0
Bethoxazin	> 0.77
Bethoxazin/Propiconazole	0.65-0.74
(1:1)	0.15-0.32
Bethoxazin/Propiconazole/ Tebuconazole (2:1:1)	0.54-1.11
Bethoxazin/Bardap 26 (1:5)	> 6.2
Bardap 26	0.58-1.18
Bardap 26/Bethoxazin/ Cyproconazole (10:2:1)	

A Toxic Limit Value of $>7.0\text{kgm}^{-3}$ indicates that at the concentrations tested, the highest of which was 7.0kgm^{-3} , no effective protection of the wood was achieved.

Using the conventions of EN113, the following toxic limit values are expressed as individual active ingredients and mixtures. Therefore, taking tebuconazole as an example, the table below shows that the amount of tebuconazole required for effective preservation dropped from $>7\text{kgm}^{-3}$ when applied on its own to 0.08kgm^{-3} when it was part of a Bethoxazin/Propiconazole/Tebuconazole mixture.

Table 2

<u>Fungicide</u>	<u>Effective Retention of</u>					
	<u>Tebuconazole</u>	<u>Cyproconazole</u>	<u>Propiconazole</u>	<u>Bethoxazin</u>	<u>Bardap 26</u>	<u>Mixture</u>
Bethoxazin	-		-	>0.77	-	-
Tebuconazole	>7.0		-	-	-	-
Cyproconazole	-	1.25	-	-	-	-
Propiconazole	-		>7.0	-	-	-
Bethoxazin/ Propiconazole	-		0.345	0.345	-	0.69
Bethoxazin/Propiconazole/ Tebuconazole	0.8		0.08	0.16	-	0.32
Bethoxazin/Bardap 26	-		-	0.185	0.925	1.11
Bardap 26	-		-	-	>6.2	-
Bardap/Bethoxazin/ Cyproconazole	-	0.068	-	0.14	0.68	0.88

Where the lower toxic limit value provides a weight loss of 10% m/m or greater, then the upper toxic limit value has been used to indicate the probable effective retention of preservative; this is in accordance with EN113.

From this data, it can be seen that combinations of these organic biocides with Bethoxazin provide a significant enhancement in preserving ability towards microfungi that attack wood in contact with soil. The oxathiazine and the triazole/quaternary ammonium compound work synergistically to protect the wood substrate from fungal attack.

The results have been plotted in Figures 2, 3, 4 and 5 which show expected effect of combining the various biocides at the ratios tested with the actual results obtained for the combinations of biocides.

A further demonstration of synergism can be derived by

calculating a synergistic index value (SI) as described above. This compares the toxic threshold obtained in the test (Table 3) with the theoretical values which can be derived from Figures 2-5.

These results are provided in the following table.

Table 3

Formulation	Toxic threshold value (kgm^{-3} ai)	Theoretical value (kgm^{-3} ai)	Synergistic Index (SI)
Bethoxazin/ Propiconazole (1:1)	0.69	1.4	2.03
Bethoxazin/Propiconazole/ Tebuconazole (2:1:1)	0.32	1.4	4.37
Bethoxazin/Bardap 26 (1:5)	1.11	2.7	2.43
Bardop 26/Bethoxazin/ Cyproconazole	0.89	1.065	1.20


These values clearly show significant synergism at the ratios tested. In the case of the 3-way combination, some additional synergy is noted over and above that derived from either a combination of Bethoxazin plus azole or Bethoxazin plus Bardap 26.

CLAIMS

1. A preservative composition comprising, in synergistic proportions, an oxathiazine compound plus one or more of a quaternary ammonium compound and a triazole compound.

2. A composition as claimed in claim 1 which comprises an oxathiazine compound, a quaternary ammonium compound and a triazole compound.

3. A composition as claimed in claim 1 or claim 2 wherein the oxathiazine compound is a compound of formula (I)



(I)

wherein n is 0, 1 or 2; R¹ is hydrogen, C₁-C₄ linear or branched alkyl, or benzyl; and

R is:

(a) phenyl; naphthyl; phenyl substituted with 1 to 3 of the following substituents:

hydroxyl, halo, C₁-C₁₂ alkyl, C₅-C₆ cycloalkyl, trihalomethyl, phenyl, C₁-C₅ alkoxy, C₁-C₅ alkylthio, tetrahydropyranyloxy, phenoxy, (C₁-C₄ alkyl)carbonyl, phenylcarbonyl, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, carboxy or its alkali metal salt, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄ alkyl)aminocarbonyl, phenylaminocarbonyl, tolylaminocarbonyl, morpholinocarbonyl, amino, nitro, cyano, dioxolanyl, or (C₁-C₄ alkoxy)iminomethyl;


pyridinyl; thienyl, preferably when n is not 2; furanyl; or thienyl or furanyl substituted with 1 to 3 of the

following groups:

alkyl, alkoxy, alkylthio, alkoxycarbonyl, halogen, trihalomethyl, cyano, acetyl, benzoyl, nitro, formyl, alkoxyaminomethyl, phenyl, or phenylaminocarbonyl, wherein the alkyl or alkoxy moiety is C₁-C₄, linear or branched;


or

(b)



wherein X is oxygen or sulfur; Y is nitrogen, -CH-, or -C(C₁-C₄ alkoxy)-; and R'' is hydrogen or C₁-C₄ alkyl.

4. A composition as claimed in claim 3 wherein the oxathiazine compound is a compound of formula (II)



(II)

wherein n is 0, 1 or 2, R¹ is hydrogen, C₁-C₄ linear or branched alkyl, or benzyl; and Q is:

(a)



wherein R², R³ and R⁴ are, individually, hydrogen, alkyl, alkoxy, alkylthio, alkoxycarbonyl, halogen, trihalomethyl, cyano, acetyl, formyl, benzoyl, nitro, alkoxyaminomethyl, phenyl, or phenylaminocarbonyl,

wherein the alkyl or alkoxy moieties are all C_1-C_4 , linear or branched, with the proviso that at least one of R^2 , R^3 or R^4 must be other than hydrogen;

(b)




wherein R^5 , R^6 and R^7 are, individually, hydrogen, C_1-C_4 alkoxy, C_1-C_4 alkylthio, halogen, trihalomethyl, cyano, acetyl, formyl, benzoyl, nitro, phenyl, or phenylaminocarbonyl, with the proviso that at least one of R^5 , R^6 or R^7 must be other than hydrogen;

(c)



wherein R^8 , R^9 and R^{10} are, individually, hydroxyl, halo, C_1-C_{12} alkyl, C_5-C_6 cycloalkyl, trihalomethyl, phenyl, C_1-C_5 alkoxy, C_1-C_5 alkylthio, tetrahydropyranyloxy, phenoxy, $(C_1-C_4$ alkyl)carbonyl, phenylcarbonyl, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, carboxy or its alkali metal salt, $(C_1-C_4$ alkoxy)carbonyl, $(C_1-C_4$ alkyl)aminocarbonyl, phenylaminocarbonyl, tolylaminocarbonyl, morpholinocarbonyl, amino, nitro, cyano, dioxolanyl, or $(C_1-C_4$ alkoxy)iminomethyl; or


(d)




wherein X is oxygen or sulfur; Y is nitrogen, $-CH-$, or $-C(C_1-C_4 \text{ alkoxy})-$; and R'' is hydrogen or C_1-C_4 alkyl.

5. A composition as claimed in claim 4 wherein the oxathiazine compound is selected from 3-(benzo[b]thien-2-yl)-5,6-dihydro-1,4,2-oxathiazine 4-oxide and 5,6-dihydro-3-(2-thienyl)-1,4,2-oxathiazine, 4-oxide.

6. A composition as claimed in any one of the preceding claims wherein the triazole compound is selected from compounds of formula (A):




wherein R_1 represents a branched or straight chain C_{1-5} alkyl group and R_2 represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or C_{1-3} alkyl, C_{1-3} alkoxy, phenyl or nitro groups and compounds of formula (B):



wherein R_3 is as defined for R_2 above and R_4 represents a hydrogen atom or a branched or straight chain C_{1-5} alkyl group.

7. A composition as claimed in claim 6 wherein the triazole compound is selected from the group comprising tebuconazole, propiconazole, azaconazole, hexaconazole, difenaconazole, cyproconazole, bromuconazole, epoxiconazole, metconazole, triticonazole, fenbuconazole, flusilazole, tetraconazole and penconazole.


8. A composition as claimed in any one of the preceding claims wherein the quaternary ammonium compound is selected from compounds of formula (III):



(III)

wherein R is an alkyl group having between 6 and 18 carbon atoms and X^- is an anion which allows ready water solubility of the quaternary ammonium salt,


compounds of formula (IV):




(IV)

wherein R_1 and R_2 are alkyl groups which may be the same or different and which contain between 6 and 18 carbon atoms, and X^- is an anion as described above,

compounds of formulae (V) or (VI):




(V)




(VI)

wherein R_1 and R_2 are alkyl groups which can be the same or different and which contain between 6 and 18 carbon atoms and X^- is an anion as described above,

compounds of formulae (VII) or (VIII):



(VII)



(VIII)

wherein R_1 and R_2 are alkyl groups which may be the same or different and which contain between 6 and 18 carbon atoms and wherein m is a number between 1 and 20.

9. A method of treating a substrate of wood or other material which comprises applying to the substrate a composition as claimed in any one of the preceding claims.


10. A method as claimed in claim 9 wherein the substrate is affected by or at risk of being affected by soft rot.

11. A method as claimed in claim 9 or claim 10 wherein the substrate is affected by or at risk of being affected by *Ascomycotina* or *Deuteromycotina*.

12. A method of preserving wood or other material which comprises applying to the wood or other material a composition as claimed in any one of claims 1 to 8.

13. Use of a quaternary ammonium compound or a triazole to enhance the activity of an oxathiazine against *Ascomycotina* and *Deuteromycotina*.

FIG. 1



20241113 09535060

Figure 2

Synergism between Bethoxazin and Propiconazole




Figure 3

Synergism between Bethoxazin, Tebuconazole and Propiconazole

Retention of Bethoxazin




Figure 4

Synergism between Bethoxazin and Bardap26





Figure 5**Synergism between Bardap26, Bethoxazin and Cyproconazole**

Retention of Cyproconazole



FOR UTILITY PATENT APPLICATION 37 C.F.R. § 1.63		Attorney Docket No. <u>H8610/</u>	
		First Named Inventor <u>Gareth Williams</u>	
		COMPLETE IF KNOWN	
<input type="checkbox"/> Declaration submitted with initial filing	<input checked="" type="checkbox"/> Declaration submitted after initial filing (Surcharge (37 CFR 1.16(e)) required)	Application Number _____ Filing Date _____ Group Art Unit _____ Examiner Name _____	

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

WOOD PRESERVATIVE FORMULATIONS

the specification of which (check only one item below):

☐ is attached hereto
☐ was filed as United States Application Serial No. _____ and was amended on _____ (if applicable).
☒ was filed as PCT International Application Number PCT/GB99/03997 on 30 November 1999 and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 CFR 1.56.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Claimed	Certified Copy Attached?
			<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO	<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)




I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s) or PCT international application(s) designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

FAX RECEIVED

JAN 18 2002

PETITIONS OFFICE

0556933 011000

U.S. APPLICATIONS			STATUS (Check One)		
U.S. Application Number	U.S. Filing Date (MM/DD/YYYY)		Patented	Pending	Abandoned
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT Application No.	PCT Filing Date	U.S. Serial Numbers Assigned (if any)			
<p>POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)</p> <p>Roger T. Frost 22,176; Charles Y. Lackey 22,707; Anthony B. Askew 24,154; John M. Harrington 25,592; Robert E. Richards 29,106; Donald R. Andersen 28,280; John S. Pratt 29,476; A. Jose Cortina 29,733; James L. Ewing, IV 30,630; Stephen M. Schatzel 31,418; James D. Johnson 31,771; Charles W. Calkins 31,814; Larry A. Roberts 31,871; Jamie L. Greene 32,467; George T. Marcou 33,014; Dean W. Russell 33,452; Richard T. Peterson 35,320; Charles T. Simmons 35,539; Tracy W. Druce 35,493; Eleanor M. Musick 35,623; Nora M. Tocups 35,17; Bruce D. Gray 35,799; Theodore R. Harper 35,890; Geoff L. Sutcliffe 36,348; Dean W. Russell 33,452; Leona G. Young 37,268; David P. LeGroy 37,869; Suzanne Seaville Shope 37,933; Mitchell G. Stockwell 39,389; Jeffrey B. Arnold 39,540; Suil Kang 39,723; Mary Anthony Merchant 39,771; Brenda Ozari Holmes 40,339; Lisa J. Moyles 40,737; Michael J. Turton 40,852; Yonche L. Kundupoglu 41,130; Scott Zimmerman 41,390; Kimberly J. Prior 41,483; Alana G. Kriegsman 41,747; Theodore M. Green 41,801; J. Steven Gardner 41,773; Joni Stutman 42,173; James J. Bindseil 42,326; Heather D. Cernicheal 42,389; Thomas A. Corrado 42,439; John K. McDonald 42,880; Sima Singadia Kulkarni 43,742; Camilla C. Williams 43,992; Christopher J. Chan 44,070; J. K. Wang 44,393; John W. Bell, Jr. 44,433; Dawn-Marie Bey 44,442; Tiep H. Nguyen 44,465; John M. Brieki 44,562; Michael J. Dimino 44,657; Kristin L. Johnson 44,807; J. Jason Link 44,874; Paul E. Knowlton 44,842; Bambi F. Walters 45,197; Cheryl L. Huseman 45,392; Shelby B. Grier 45,785; Jennifer R. Seng 45,851; Valbhav P. Kodaba 45,865; Greg Moldafsky 46,514; J. Michael Boggs 46,563; Michael K. Dixon 46,665; Tywanda L. Harris 46,758; Kristin D. Mallatt 46,896; Cynthia R. Rothschild 47,040; John C. Alemani 47,384; Geoffrey K. Gavin 47,591; Janina Malone 47,758; Robert M. Stevens 47,872</p> <p>I acknowledge the above-listed attorneys and agents and their firm Kilpatrick Stockton LLP represent my employer (if I am an employee and this application has been or will be assigned to my employer) or the entity with which I have contracted (if I am an independent contractor and this application has been or will be assigned to such entity) and in such cases do not represent me individually. I further acknowledge I have not established, nor will I seek to establish, any personal attorney/client relationship with Kilpatrick Stockton LLP in connection with this application and understand that, should I require legal representation, I will obtain such, at my expense, other than through Kilpatrick Stockton LLP.</p>					
Send Correspondence to:			John S. Pratt, Esq. Kilpatrick STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, GA 30309-4530 Phone: (404) 815-6367 Fax: (404) 815-6555		
 23370 PATENT TRADEMARK OFFICE					
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issuing thereon.</p>					
Name of Sole or First Inventor:		Gareth Williams			
Inventor's Signature and Date:				Date: 18.09.01	
Residence Address and Citizenship:		89 LENFELDS, NEWTON		Citizenship: GB	
Post Office Address:		WILKELD W46 4SH UK GBX			
Name of Additional Joint Inventor, if any:		Michael Bacon			
Inventor's Signature and Date:				Date: 18.09.01	
Residence Address and Citizenship:		ST BRINDLE PARK DRIVE		Citizenship: GB	
Post Office Address:		CASTLEFORD W46 4SH UK GBX			
Name of Additional Joint Inventor, if any:					
Inventor's Signature and Date:					
Residence Address and Citizenship:					
Post Office Address:					